2022年欧洲生物仿制药竞争的影响（英）

The 8th iteration of the ‘Impact of Biosimilar Competition in Europe’ report describes the effects on price, volume, and market share following the arrival of biosimilar competition in Europe. The report consists of observations on competitive markets, and a set of Key Performance Indicators (KPIs) to monitor the impact of biosimilars in 23 European markets. The report has been a long-standing source of information on the status of the biosimilars market.

Biosimilars are a critical part of the European healthcare system, and are able to balance spending by generating savings for payers, create headroom for innovation, and expand access to biologic therapy for patients. Since the first biosimilar was launched in 2006, biosimilar medicines have become a corecomponent of an effective healthcare system, but headwinds are increasing with the challenges of orphan biosimilar development, and the disparity in access across Europe becoming more acute.

As the report adds new therapy areas, and as new classes emerge, we have new challenges that we must adapt to for this report to continue its relevance. This means that we continue to refine previous definitions to make them representative of the current environment, building on the 2020 (6th report)which permitted the classification historic dynamics in the market, and allows policymakers, national competent authorities, patient groups, and industry to view the market with greater granularity.